Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

This study is testing a personalised cancer vaccine called ADCV01 — made from the patient's own tumour cells — as an add-on treatment after standard surgery and chemoradiation for glioblastoma (GBM), the most aggressive type of brain tumour. **You may be eligible if...** - You are between 20 and 75 years old - You have been newly diagnosed with a single glioblastoma (WHO grade IV) that is not located in the brainstem or cerebellum - You are scheduled to have brain surgery to remove the tumour, and you agree to have tumour cells preserved to make the vaccine - You are reasonably functional (KPS score 70 or above) - Your kidney, liver, and blood functions meet required levels **You may NOT be eligible if...** - You have more than one brain tumour - Your tumour is in the brainstem or cerebellum - You have received any treatment inside the brain cavity (such as chemotherapy wafers) during surgery - Your organ function does not meet required levels Talk to your doctor to see if this trial is right for you.